JP2023536497A5 - - Google Patents

Info

Publication number
JP2023536497A5
JP2023536497A5 JP2023507480A JP2023507480A JP2023536497A5 JP 2023536497 A5 JP2023536497 A5 JP 2023536497A5 JP 2023507480 A JP2023507480 A JP 2023507480A JP 2023507480 A JP2023507480 A JP 2023507480A JP 2023536497 A5 JP2023536497 A5 JP 2023536497A5
Authority
JP
Japan
Prior art keywords
disease
antigen peptide
dementia
pharmaceutical formulation
defined above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536497A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/071778 external-priority patent/WO2022029181A1/en
Publication of JP2023536497A publication Critical patent/JP2023536497A/ja
Publication of JP2023536497A5 publication Critical patent/JP2023536497A5/ja
Pending legal-status Critical Current

Links

JP2023507480A 2020-08-04 2021-08-04 免疫原性化合物 Pending JP2023536497A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20189425.0 2020-08-04
EP20189425 2020-08-04
PCT/EP2021/071778 WO2022029181A1 (en) 2020-08-04 2021-08-04 Immunogenic compounds

Publications (2)

Publication Number Publication Date
JP2023536497A JP2023536497A (ja) 2023-08-25
JP2023536497A5 true JP2023536497A5 (enExample) 2024-08-13

Family

ID=72178339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507480A Pending JP2023536497A (ja) 2020-08-04 2021-08-04 免疫原性化合物

Country Status (10)

Country Link
US (1) US20230287050A1 (enExample)
EP (1) EP4192493A1 (enExample)
JP (1) JP2023536497A (enExample)
KR (1) KR20230044524A (enExample)
CN (1) CN116261464A (enExample)
AU (1) AU2021322080A1 (enExample)
CA (1) CA3185563A1 (enExample)
IL (1) IL300364A (enExample)
MX (1) MX2023001483A (enExample)
WO (1) WO2022029181A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240147981A (ko) * 2022-02-09 2024-10-10 에이씨 이뮨 에스에이 항-알파시누클레인 치료 백신
AU2024211543A1 (en) 2023-01-26 2025-07-17 Ac Immune Sa Liposomal construct
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2361928T3 (pl) 2003-05-19 2017-09-29 Prothena Biosciences Limited Skrócone fragmenty alfa-synukleiny w chorobie z ciałami Lewy'ego
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
SI2723379T1 (sl) * 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
RU2734924C2 (ru) 2015-11-03 2020-10-26 Аффирис Аг Способ вакцинации против аутоантигена у пациента-человека
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
EP3638298A4 (en) * 2017-06-16 2021-05-05 United Neuroscience PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN-PROTEIN AND FORMULATIONS THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHIA
US20230074436A1 (en) * 2019-09-20 2023-03-09 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2023536497A5 (enExample)
RU2011100126A (ru) Применение мимотопов для лечения бетта-амилоидозов
RU2011100125A (ru) Соединения для лечения амилоидозов
RU2007145052A (ru) Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера
KR102869640B1 (ko) 항-aveta 치료적 백신
JP2022529529A5 (enExample)
HUE031860T2 (en) PCSK9 vaccine
HK1249859A1 (zh) Pcsk9肽疫苗
TW201345927A (zh) 組成物
US20250152684A1 (en) Anti-Alpha-Synuclein Therapeutic Vaccines
US20230287050A1 (en) Immunogenic Compounds
JP2025506472A5 (enExample)
CN104507966B (zh) 基于补体组分c5a的疫苗
CN118660717A (zh) 抗α-突触核蛋白的治疗性疫苗
EA051687B1 (ru) Терапевтические вакцины против альфа-синуклеина
JP2012510794A5 (enExample)
EP2532359A1 (en) CETP fragments
WO2024156908A1 (en) Liposomal construct
JP2024538615A5 (enExample)
TW201348264A (zh) 組成物
HK1170248A (en) Immunogenes peptide